loading
Telix Pharmaceuticals Ltd Adr stock is traded at $12.48, with a volume of 156.07K. It is up +3.23% in the last 24 hours and down -23.34% over the past month. Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$12.09
Open:
$12.4
24h Volume:
156.07K
Relative Volume:
2.95
Market Cap:
$4.22B
Revenue:
$417.75M
Net Income/Loss:
$32.27M
P/E Ratio:
128.00
EPS:
0.0975
Net Cash Flow:
-
1W Performance:
+8.15%
1M Performance:
-23.34%
6M Performance:
-36.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$12.13
$12.60
1-Week Range:
Value
$10.50
$12.60
52-Week Range:
Value
$10.50
$30.36

Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile

Name
Name
Telix Pharmaceuticals Ltd Adr
Name
Phone
-
Name
Address
-
Name
Employee
554
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
TLX's Discussions on Twitter

Compare TLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TLX
Telix Pharmaceuticals Ltd Adr
12.48 3.98B 417.75M 32.27M 0 0.0975
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-03-25 Initiated H.C. Wainwright Buy
Jun-05-25 Initiated Wedbush Outperform
Nov-15-24 Initiated UBS Buy

Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News

pulisher
Aug 20, 2025

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 17, 2025

Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent

Aug 17, 2025
pulisher
Aug 16, 2025

Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire

Aug 16, 2025
pulisher
Aug 13, 2025

Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent

Aug 13, 2025
pulisher
Aug 09, 2025

Telix Pharmaceuticals under investigation for potential securities fraud. - AInvest

Aug 09, 2025
pulisher
Aug 08, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 08, 2025
pulisher
Aug 05, 2025

Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aug 05, 2025
pulisher
Aug 05, 2025

Telix Pharmaceuticals under investigation for securities fraud, ADR price falls. - AInvest

Aug 05, 2025
pulisher
Aug 03, 2025

Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aug 03, 2025
pulisher
Aug 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Investors to Connect - ACCESS Newswire

Aug 01, 2025
pulisher
Aug 01, 2025

Telix Pharmaceuticals under investigation for alleged securities fraud. - AInvest

Aug 01, 2025
pulisher
Jul 31, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 31, 2025
pulisher
Jul 29, 2025

Telix Announces H1 2025 Earnings Date: Global Investors Briefing Set for August 21 - Stock Titan

Jul 29, 2025
pulisher
Jul 28, 2025

Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 28, 2025
pulisher
Jul 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Telix Pharmaceuticals Limited (TLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire

Jul 27, 2025
pulisher
Jul 25, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 25, 2025
pulisher
Jul 23, 2025

Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com

Jul 23, 2025
pulisher
Jul 22, 2025

Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan

Jul 22, 2025
pulisher
Jul 09, 2025

Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan

Jul 09, 2025
pulisher
Jul 03, 2025

H.C. Wainwright initiates Telix Pharmaceuticals stock with Buy rating on radiotherapy portfolio - Investing.com

Jul 03, 2025
pulisher
Jun 23, 2025

FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan

Jun 23, 2025
pulisher
Jun 20, 2025

Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan

Jun 20, 2025
pulisher
Jun 11, 2025

Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan

Jun 11, 2025
pulisher
Jun 03, 2025

Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan

Jun 03, 2025
pulisher
May 26, 2025

5 of the best ASX 200 shares to buy in June - The Motley Fool Australia

May 26, 2025
pulisher
May 22, 2025

Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan

May 22, 2025
pulisher
May 07, 2025

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan

May 07, 2025
pulisher
Apr 28, 2025

Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan

Apr 28, 2025
pulisher
Apr 22, 2025

Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan

Apr 22, 2025
pulisher
Apr 15, 2025

Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan

Apr 15, 2025
pulisher
Apr 08, 2025

Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

Telix Pharmaceuticals appoints new CTO - Investing.com

Apr 07, 2025
pulisher
Apr 03, 2025

Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan

Apr 03, 2025
pulisher
Apr 01, 2025

Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan

Apr 01, 2025
pulisher
Mar 21, 2025

FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club

Mar 20, 2025
pulisher
Mar 20, 2025

Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club

Mar 20, 2025
pulisher
Mar 17, 2025

Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan

Mar 17, 2025
pulisher
Mar 12, 2025

Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan

Mar 12, 2025
pulisher
Mar 03, 2025

Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan

Mar 03, 2025
pulisher
Feb 25, 2025

Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

特斯拉將收購德國Manz部分資產 增強德國自動化實力 - Yahoo 財經

Feb 25, 2025
pulisher
Feb 24, 2025

〈強茂展望〉擴大海外布局 越南廠最快2026年量產 - Yahoo 財經

Feb 24, 2025
pulisher
Feb 21, 2025

Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada

Feb 21, 2025
pulisher
Feb 20, 2025

Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan

Feb 20, 2025

Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):